AbstractA series of C10‐position imidazole‐modified catalpol derivatives are specifically designed and synthesized for serving as potential pancreatic cancer inhibitors, which are characterized by 1H NMR, 13C NMR and high‐resolution mass spectrometry (HRMS). They were evaluated by the 3‐[4, 5‐dimethylthiazol‐2‐yl]‐2, 5‐diphenyltetrazolium bromide (MTT) test on two human pancreatic cancer cells PANC‐1, BxPC‐3 and normal pancreatic cell HPDE6‐C7, which showed the significant inhibitory effected on the growth of human pancreatic cancer cells of PANC‐1 and BxPC‐3, especially 91.6% efficacy on BxPC‐3, and 73.1% on PANC‐1. Simulation studies like molecular docking supported strong binding of vascular endothelial growth factor receptor 2 (VEGFR‐2) protein tyrosine kinase (PDB ID: 4AGD), a target of pancreatic cancer. A novel imidazol‐modified catalpol compound 3i with strong inhibitory effect on pancreatic cancer cells, which could potentially develop into anti‐pancreatic cancer drug candidates in the future.

1996-12-01·Asian Pacific journal of allergy and immunology4区 · 医学

A study of cell-mediated immune response to pancreatic antigens in patients with fibrocalculous pancreatic diabetes.

4区 · 医学

Article

作者: Vannasaeng, S ; Kespichayawatana, W ; Sarasombath, S ; Tandhanand-Banchuin, N

In order to investigate whether there was any association between autoimmunity to pancreatic antigens with FCPD as well as IDDM, cell-mediated immune response to pancreatic antigens was studied by lymphoproliferation assay in 7 FCPD, 17 IDDM, 33 NIDDM patients and 102 normal controls. Optimal pancreatic antigen concentrations used were 100, 150 and 200 micrograms/ml. Positive results were considered for each concentration of antigens tested, at stimulation index (SI) > (mean +/- 2 SD) SI obtained from normal age-matched controls with the use of the corresponding concentration of antigen. The one who gave positive result with any of these optimal antigen concentrations was considered to be the responder to pancreatic antigens. With this criterion, the responders were found to be 3/7 (42.9%) FCPD, 6/17 (35.3%) IDDM and 6/33 (18.2%) NIDDM patients; while there were 11 of all 102 (10.8%) normal controls.

100 项与 Pancreatic Cancer(Divide and Conquer) 相关的药物交易

登录后查看更多信息